21.02.2018 | Letter to the editor
Administrating docetaxel, doxorubicin, and cyclophosphamide as a neoadjuvant treatment may decrease lymphedema risk in breast cancer patients
Erschienen in: Supportive Care in Cancer | Ausgabe 6/2018
Einloggen, um Zugang zu erhalten